Why Kite Pharma Investors Should Expect Lymphoma Treatment FDA Approval In 2017

H.C. Wainwright reiterated its Buy rating on Kite Pharma Inc KITE on expectations that its cancer drug KTE-C19 would be approved in 2017 given more granular data on hand.

“Given that KTE-C19 has demonstrated positive results in DLBCL (including relapsed and refractory subgroups), PMBCL, and TFL patients, we expect the FDA to accept a broad label for KTE-C19, assuming it is approved later in 2017 for a conservative timeline of a 2018 launch,” analyst Corey Davis wrote in a note.

Davis maintains his $78 price target on the stock, which was down 7.63 percent at time of writing to $47.20.

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: Analyst ColorBiotechHealth CarePrice TargetReiterationFDAAnalyst RatingsMoversGeneralCorey DavisH.C. Wainwright
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!